Total Credits: .75 including .75 AOA Category 1-A Credit(s)
Coronary artery disease (CAD) is highly prevalent and is the major cause of morbidity and mortality in diabetic patients. Patients with diabetes and mixed hyperlipidemia should control glucose, blood pressure and lipid levels; however, less than 20 percent of patients are at goal for all three. With new medications and treatment modalities available, physicians must have an understanding of these latest advancements to effectively manage diabetic patients.
At the conclusion of this session, the participant should be able to:
Disclosure Statement: The speaker discloses he is a consultant for Zoll and Amgen and serves on the speaker’s bureau for Amgen, Astra Zeneca, Boehringer Ingelheim/Lilly, and Zoll. All of the relevant financial relationships listed have been mitigated.
Accreditation Statement: The Pennsylvania Osteopathic Medical Association (POMA) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. POMA designates this live activity for a maximum of 0.75 Category 1-A AOA CME credits and will report CME and specialty credits to the AOA commensurate with the extent of the physician’s participation in this activity.
Grievance Statement: If you are not satisfied with the program, you may file a written grievance by emailing cme@poma.org. Your complaint will be forwarded to the Education Committee for review. The committee will determine if the participant should be reimbursed with no credits or deny the complaint and take the issue into consideration for future programs.
| POMA D8 22 -Gabriel - Handout (3.39 MB) | Available after Purchase | ||
George P. Gabriel, DO, FACC, “Cardiovascular Risk Reduction for the Diabetic Patient,” is director of clinical cardiology at Allegheny Health Network in Pittsburgh. Board certified in internal medicine and cardiovascular diseases, he is a 1990 graduate of the Philadelphia College of Osteopathic Medicine. He completed an internship at PCOM, an internal medicine residency at the Cleveland Clinic in Ohio, and a cardiovascular diseases fellowship at Albert Einstein Medical Center in Philadelphia. A fellow of the American College of Cardiology, Dr. Gabriel is a member of POMA. Dr. Gabriel discloses he is a consultant for Zoll and Amgen and serves on the speaker’s bureau for Amgen, Astra Zeneca, Boehringer Ingelheim/Lilly, and Zoll. All of the relevant financial relationships listed have been mitigated.
|
Orthopedic Injuries: Management in the Primary Care Office and Splinting
Original Program Date: 01/29/2022 |